22 years of struggle, the final listing, Gan Li Pharmaceuticals vowed to "insulin" domestic substitution to the end.

Guide: "Kaiming Ventures" ten years of help, Gan Li Pharmaceuticals today successfully listedyears of struggle, Gan Li Pharmaceuticals finally successfully listed today, as the domestic three generations of insulin leading enterprises, gan Li Pharmaceutical's success for the A-share market biopharmaceutical sector to add another "strong general", the issue price of 63.32 yuan / share, the issue price-earnings ratio of 22.99 timesToday's opening price of 91.18 yuan / share, the top price rose 44%, the market value of 36.572 billion yuan, more than Tonghua Dongbao 4.01 billion yuanIn just one day, the total market capitalisation jumped 31 places in the industryon the other hand, known as "insulin in Maotai" Gan Li Pharmaceutical sanhit A-share road was finally successful, so smooth listing, June 18, Gan Li Pharmaceuticals new share subscription results came out when actually had been expected, the same day online investors subscribed a total of about 4006.19 million shares, the contribution subscription amount of about 2.536 billion yuan, the subscription rate reached 99.58 percentGan Li Pharmaceutical selling product directionAccording to Gan Li Pharmaceuticals, the public offering of shares will provide financial support for the expansion of Gan Li Pharmaceutical's production capacity, the construction of marketing network and overseas clinical registration applications, further consolidating and enhancing Gan Li Pharmaceutical's market positionas a leading domestic insulin industry, Ganli Pharmaceuticals in the field of biosynthetic insulin product coverage, research and development technology, etcare in the leading domestic levelAt present, the company has a long-acting insulin glargine, quick-acting insulin and sperm protein zinc recombinant insulin mixed injection (25R), Mendong insulin four recombinant insulin similar species, comprehensive coverage of long-acting, quick-acting, medium-effect three insulin functional market segmentsheavyweight brands include "Long Show" and "Fast Show"Recombined insulin insulin injections (Chang Xiuyu) are currently the most important source of income for Ganli Pharmaceuticals, with sales revenue accounting for 91.51 percent, 94.74 percent and 87.91 percent of the main business income from 2017 to 2019, respectivelythe domestic market situation of insulin
in recent years, with the domestic diabetes prevalence rate is gradually rising trend, insulin market development potential is considerableAccording to statistics, in 2019, China's insulin market size is about 20 billion yuanAlthough China's insulin market has achieved high-speed growth, but in reference to the development of the developed countries, only 2% of patients with diabetes using insulin-type drugs to control blood sugar, the domestic market still has great potential for developmentbut in the face of this huge growth rate of the market, the domestic insulin market is widely monopolized by multinational enterprises, market concentration is quite highNovo Nordisk, Lilly and Sanofi have a combined market share of nearly 70%and with the rise of emerging biological products enterprises such as GanLi Pharmaceuticals and the trend of domestic substitution to reduce drug prices, the overall sales revenue of Ganli Pharmaceuticals and the sales of insulin preparations have achieved considerable growthIn 2019, the Company achieved operating income of RMB2.895 billion, up 21.26% YoY, and net profit of RMB1,167 million, up 24.98% YoYAmong them, insulin preparation revenue of 2.753 billion yuan, accounting for 95.1%Gan Li Pharmaceuticals to fight against the three major advantages of theGan Li Pharmaceuticals on the one hand in order to provide the general population with more cost-effective quality drugs needs, on the other hand, in order to more in line with the state-advocated high-quality domestic drug substitution policy, at the same time in order to combat the multinational enterprises on the "insulin" market dominanceGan Li Pharmaceuticals as a process enterprise with the three inherent advantages for the company to gradually realize the import substitution of China's insulin market to create a good development opportunityproduct price advantage: compared with imported recombinant insulin analogues, Ganli pharmaceutical products have a clear price advantage, the main product "Long Xiuyu" price is about 20% lower than similar imported products, can significantly reduce the medical burden of diabetic patients, and effectively control medical expenses at the same time so that more diabeticpatients can receive cost-effective recombinant insulin analogue treatmentrich product reserve and product line layout advantages: at present, Glycol Pharmaceuticals has a long-acting insulin glargine, quick-acting insulin, the company's door-to-winter insulin and sperm protein zinc recombinant recombinant recombinant insulin mixed injection (25R) four recombinant insulin-like species, covering long-lasting, quick-acting, medium-effect three insulin function market segmentsWith the increase of ipo financing and research and development investment, the future product line will be further enriched, as a recombinant insulin analogue product line of the production enterprises, to better grasp the rapid development of the insulin market market opportunitiescore technical advantages: Gan Li Pharmaceuticals master three generations of insulin core technology, is the first domestic manufacturers with both insulin glargine and mendong insulinAnd the progress of research and development also belongs to the domestic leading, in addition to Tonghua Dongbao and the federal pharmaceutical, other enterprises are relatively backward in progress, the overall domestic market competition pattern is good, the advantages of enterprises are very obviousbehind the scenes: "Qiming Ventures" is indispensable
in addition, in this successful listing of Gan Li Pharmaceuticals at the same time, as the behind-the-scenes pusher of "Qiming Ventures" is also very popular, it can be said that Gan Li Pharmaceuticals can be listed, Qiming Ventures is definitely the biggest helpand Qiming Ventures, Gan Li Pharmaceuticals can be listed, but also successfully make "Qiming Ventures" ushered in the year's fifth listed enterprisesStone Technology (688169 SH), Schrdinger (NASDAQ: SDGR), Sanyou Medical (688085 SH), Shenzhou Cell (688520 SH) is a very successful case a decade of companionship, no unique vision is absolutely not possible, in 2010, Qiming Ventures exclusive investment gan Li Pharmaceutical's first round of financing; Qiming Ventures is now the largest institutional investor before Ganli Pharmaceuticals went public as the biggest contributor between Qiming Ventures and Gan li Pharmaceuticals: Liang Yu finally put her first biopharmaceutical project invested after Qiming Ventures to the capital market, plus her precision "capture" since then re-Ding Pharmaceuticals, Kangsino Bio and other innovative pharmaceutical companies, can be described as a great success finally, focusing on the development speed of the domestic pharmaceutical industry in recent years, i have to feel the crucial role played by venture capital enterprises, in the land of large and large things in China, "thousands of miles" may not be as little as thought, the lack of perhaps is like Qiming venture-like "Bole." It is hoped that with the expansion of the stage of the Chinese market, more Bole and Chili Ma can meet here, with the spark of the dragonfly, can push The Chinese medical cause to a higher level .